Urogen Pharma (NASDAQ:URGN) Stock Rating Upgraded by Jefferies Financial Group

Urogen Pharma (NASDAQ:URGN) was upgraded by equities researchers at Jefferies Financial Group to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. Finally, Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.13.

Urogen Pharma Price Performance

Shares of NASDAQ URGN opened at $24.11 on Friday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00. The company’s 50-day moving average is $20.11 and its 200 day moving average is $21.16. The stock has a market capitalization of $1.17 billion, a P/E ratio of -7.53 and a beta of 1.43.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.12. The company had revenue of $37.84 million for the quarter, compared to analysts’ expectations of $39.92 million. Research analysts anticipate that Urogen Pharma will post -1.45 earnings per share for the current year.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the sale, the general counsel owned 51,326 shares of the company’s stock, valued at $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the sale, the insider directly owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares in the last quarter. State of Wyoming bought a new position in shares of Urogen Pharma in the third quarter worth approximately $66,000. Russell Investments Group Ltd. lifted its stake in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Urogen Pharma in the third quarter worth approximately $76,000. Institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.